Mental Disorders
237
19
30
164
Key Insights
Highlights
Success Rate
96% trial completion (above average)
Published Results
31 trials with published results (13%)
Research Maturity
164 completed trials (69% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
3.0%
7 terminated out of 237 trials
95.9%
+9.4% vs benchmark
12%
28 trials in Phase 3/4
19%
31 of 164 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 164 completed trials
Clinical Trials (237)
Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression
Developing and Evaluating a Machine-Learning Opioid Overdose Prediction & Risk-Stratification Tool in Primary Care
Auricular Stimulation for Nicotine Withdrawal in Psychiatric Inpatients
A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
Hospital Cohort Survey of Public Health Post-attack of July 14, 2016
Stimulation-Induced Changes in Fronto-Limbic Network
Integrated Collaborative Care Teams for Youth With Mental Health and/or Addiction Challenges (YouthCan IMPACT)
Psychiatric Multi-omics and Neuroimaging Project
Pharmacist-led Interventions in Psychiatric Patients
Psychosocial Factors in Dual Diagnosis in a General Hospital
An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease
Exergames in Mental Health
Optimizing Chronic Pain Care With Mindfulness and Chronic Pain Management Visits
Common Factors Group Psychotherapy for General Mental Health Concerns
Braining: Implementation of Physical Exercise for Patients in Specialist Psychiatry
STIM'ZO : Examining tDCS as an add-on Treatment for Persistent Symptoms in Schizophrenia
Cognitive Outcomes After Dexmedetomidine Sedation in Cardiac Surgery Patients
Using Responsible Artificial Intelligence (AI) to Predict Online Therapy Outcome and Engagement
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)